Home › Research › How common it is
Association between sacubitril/valsartan and risk of dementia in patients with heart failure: a nationwide cohort study
Kyungyeon Jung, Ju Hwan Kim, Sungho Bea, Hwa Yeon Ko, Seng Chan You, Eue‐Keun Choi, Suehyun Lee, Minsik Lim et al.. European Heart Journal - Cardiovascular Pharmacotherapy, 2025-05-21
Topic: Risk, prevention and care in population studies
Plain-language summary
We conducted a retrospective cohort study using the National Health Insurance Database in South Korea. Patients diagnosed with HF and prescribed either sacubitril/valsartan or angiotensin-converting enzyme inhibitors (ACEIs)/angiotensin receptor blockers (ARBs) within 90 days of their first HF diagnosis between October 2017 and December 2020 were included. The primary outcome was incident dementia, categorized into Alzheimer's dementia and vascular dementia. Follow-up began after 1 year from the prescription date, to accommodate dementia onset latency, until the earliest occurrence of dementia, death, or end of study period (March 2023). After 1:4 propensity score matching, the hazard ratio (HR) with 95% confidence interval (CI) for dementia was estimated using a Cox proportional hazards model. Among 7085 sacubitril/valsartan users and 359 153 ACEI/ARB users, 6930 sacubitril/valsartan users [mean (SD) age, 61.7 (14.6) years; 70.9% male] were matched on propensity score to 27 720 ACEI/ARB users [mean (SD) age, 61.7 (15.8) years; 71.1% male]. During a mean follow-up of 2.2 and 2.3 years, dementia occurred in 200 (2.9%) sacubitril/valsartan users and 980 (3.5%) ACEI/ARB users, respectively. Sacubitril/valsartan showed a 16% lower risk of dementia compared with ACEI/ARB (HR 0.84; 95% CI 0.72-0.98). However, of 1180 cases of incident dementia, 1079 (91.4%) were categorized as Alzheimer's dementia and statistical significance was not reached in this main group. Despite plausible biological mechanisms, no association between sacubitril/valsartan and an increased risk of dementia was observed in patients with HF.
What this study adds
Evidence grade: Moderate
This is a follow-up (cohort) study. This cohort study found that sacubitril/valsartan use was associated with a 16% lower risk of dementia compared with ACEI/ARB use in patients with heart failure. Reported effect size: 70.9%; 71.1%; 2.9%.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Jung, K., Kim, J. H., Bea, S., Ko, H. Y., You, S. C., Choi, E., et al. (2025). Association between sacubitril/valsartan and risk of dementia in patients with heart failure: a nationwide cohort study. European Heart Journal - Cardiovascular Pharmacotherapy. https://doi.org/10.1093/ehjcvp/pvaf024
Vancouver
Jung K, Kim JH, Bea S, Ko HY, You SC, Choi E, et al. Association between sacubitril/valsartan and risk of dementia in patients with heart failure: a nationwide cohort study. European Heart Journal - Cardiovascular Pharmacotherapy. 2025. doi:10.1093/ehjcvp/pvaf024. PMID: 40397431.
BibTeX
@article{jung2025-40397431,
author = {Jung, Kyungyeon and Kim, Ju Hwan and Bea, Sungho and Ko, Hwa Yeon and You, Seng Chan and Choi, Eue‐Keun and Lee, Suehyun and Lim, Minsik and others},
title = {{Association between sacubitril/valsartan and risk of dementia in patients with heart failure: a nationwide cohort study}},
journal = {European Heart Journal - Cardiovascular Pharmacotherapy},
year = {2025},
doi = {10.1093/ehjcvp/pvaf024},
pmid = {40397431},
url = {https://doi.org/10.1093/ehjcvp/pvaf024}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- We conducted a retrospective cohort study using the National Health Insurance Database in South Korea.
- Patients diagnosed with HF and prescribed either sacubitril/valsartan or angiotensin-converting enzyme inhibitors (ACEIs)/angiotensin receptor blockers (ARBs) within 90 days of their first HF diagnosis between October 2017 and December 2020 were included.
- The primary outcome was incident dementia, categorized into Alzheimer's dementia and vascular dementia.
- Follow-up began after 1 year from the prescription date, to accommodate dementia onset latency, until the earliest occurrence of dementia, death, or end of study period (March 2023).
- After 1:4 propensity score matching, the hazard ratio (HR) with 95% confidence interval (CI) for dementia was estimated using a Cox proportional hazards model.
Why it matters
This cohort study found that sacubitril/valsartan use was associated with a 16% lower risk of dementia compared with ACEI/ARB use in patients with heart failure. However, most incident dementia cases were categorized as Alzheimer's dementia, and the study did not find a significant difference for vascular dementia.
New to this subject? Start with our plain-English guide: Alzheimer's in numbers →
Study details
- Study designcohort study
- Effect size70.9%; 71.1%; 2.9%
- Evidence strengthModerate
How this study scored 52/100
Published in a peer-reviewed journal, and it is a cohort study following people over time. Scored zero for sample size, studied in people and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (European Heart Journal - Cardiovascular Pharmacotherapy) |
| Journal's citation record | 0 / 4 | European Heart Journal - Cardiovascular Pharmacotherapy: journal h-index 60 (OpenAlex, 2026-10-29) |
| Study design | 7 / 12 | A cohort study following people over time |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 2 / 3 | Effect reported as a number, without an interval or test |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 2 / 7 | Cited 8 times (OpenAlex, 2026-10-10) |
| Citations per year | 1 / 5 | 2.7 citations a year over 3 year(s) since 2025 |
| Impact for its field and year | 3 / 6 | Cited 5.1× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 1 / 4 | Cited 8 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 2 / 4 | Last-listed author Ju‐Young Shin: h-index 35 (OpenAlex, whole career) |
| Institution's track record | 3 / 3 | Harvard University: institution h-index 3,235 (OpenAlex) |
| Multicenter collaboration | 3 / 3 | OpenAlex lists 10 institution(s) in 2 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 40397431) |
| Free to read | 2 / 2 | Free to read |
| Total | 52 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1093/ehjcvp/pvaf024
- PubMed: 40397431
- Original source →
- Free full text: European Heart Journal - Cardiovascular Pharmacotherapy →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Related studies in How common it is from nearby years
Also tagged “biobank”
1,084 studies in the library carry the topic tag “biobank”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,084 tagged studies.